In total, 43 people [22 adults (mean age, 33.7) and 21 children (mean age, 5.7)] were included and completed the clinical study, all presenting comparable disease severity at baseline (see SCORAD -Table 1).The participants reported applying the study product two to three times daily on average during the study period.
Overall, the study product was well tolerated, and no adverse events related to it occurred. Nine participants reported some cutaneous discomfort, redness, small pimples, or dryness, which were judged to be expected and frequently encountered in patients with mild AD.
The study product rapidly reduced disease severity in a
Overall, the study product was well tolerated, and no adverse events related to it occurred. Nine participants reported some cutaneous discomfort, redness, small pimples, or dryness, which were judged to be expected and frequently encountered in patients with mild AD.
The study product rapidly reduced disease severity in a
